Led by Caroline Huber, Associate Director of Policy and Economics, a surprising new study was recently published in The Journal of Infectious Diseases, estimating the overlooked social, economic and health impacts of the 2013-2016 West Africa Ebola crisis.
A Precision-led study recently published in ISPOR’s Value in Health examines whether budget impact models typically overestimate or underestimate real-world budget impact. PHE study authors Julia Snider, Jesse Sussell, Mahlet Tebeka, Alicia Gonzalez along with scientific advisor Peter Neumann focused on 6 ICER- BIM estimates—comparing each with ex-post estimates and determined that estimates of uptake were substantially higher than ex-post market-based estimates of use.
In a new podcast appearing on the American Journal of Managed Care (AJMC)’s Managed Care Cast, PHE Senior Research Economist James Baumgardner discusses his research on using cost variation to identify savings Opportunities under the Oncology Care Model (OCM).
A new study by Precision co-authors Andrew Delgado and Jinjoo Shim, along with scientific advisors John Romley and Katherine Batt, assesses the value to society of improved survival from novel immune-oncology treatments. With the data compiled, the study team concluded that there is evidence of substantial survival gains, and thus, social value.
In the latest edition of the Journal of Clinical Pathways (JCP), Zachary Bessette summarizes PHE Senior Research Economist Jim Baumgardner’s recent ASH presentation, focused on studying the cost-effectiveness of novel CAR-T treatments. In the study, Dr. Baumgardner’s team asserts that the introduction of CAR-T therapies represents a major break from the trend of declining incremental effectiveness and provides similar cost-effectiveness to other innovations.
For more information, or to learn how to change your cookies preferences, please click here.